Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MBS-K040 | Human | Human B7-H3(4Ig)-coupled Magnetic Beads | |||
| B73-H82F5 | Human | Biotinylated Human B7-H3 / CD276 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| B73-H82E6 | Human | Biotinylated Human B7-H3 / CD276 Protein, Avitag™,His Tag |  |
|
|
| B73-H52E2 | Human | Human B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-H5253 | Human | Human B7-H3 / CD276 Protein, Fc Tag (MALS verified) |  |
|
|
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Monoclonal antibody 8H9 I-124 | 124I-8H9; 124I-8H9-(B7-H3) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Glioma | Details |
| Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
| CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Shenzhen University General Hospital | Details | ||
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Second Affiliated Hospital Of Guangzhou Medical University | Details | ||
| DS-5573 | DS-5573; DS-5573a | Daiichi Sankyo Co Ltd | Details | ||
| B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details | |||
| B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
| Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Sarcoma, Synovial; Melanoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Neuroblastoma; Neurofibrosarcoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
| 4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
| SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Neoplasms, Germ Cell and Embryonal; Melanoma; Choroid Plexus Neoplasms; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Solid tumours; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Desmoplastic Small Round Cell Tumor; Rhabdoid Tumor; Carcinoma; Hepatoblastoma; Rhabdomyosarcoma; Ependymoma; Teratoma; Medulloblastoma | Details |
| B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
| Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
| Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
| TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
| Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Sarcoma, Ewing; Osteosarcoma; Neuroblastoma; Urethral Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Abdominal Neoplasms; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Ovarian Neoplasms; Solid tumours | Details |
| TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
| Vobramitamab duocarmazine | MGC-018 | Phase 3 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Pancreatic Ductal; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
